BUDGET IMPACT OF DURVALUMAB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE STAGE III NONSMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

被引：0
|
作者：
Meirelles, I [1 ]
Costa, N. [1 ]
Dias, C. [2 ]
Massaoka, M. [2 ]
Lopes, D. G. [2 ]
Jabase, L. [3 ]
机构：
[1] IQVIA Real World Insights, Sao Paulo, SP, Brazil
[2] AstraZeneca, Cotia, Brazil
[3] AstraZeneca, Cotia, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE386
引用
收藏
页码：S125 / S125
页数：1
相关论文
共 50 条
  • [21] Durvalumab treatment initiation delays in patients with unresectable stage III non-small cell lung cancer treated at Veterans Health Administration facilities.
    Datta, Paromita
    Moore, Amanda
    Frei, Christopher R.
    Reveles, Kelly R.
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Alkadimi, Munaf
    Whitehead, Jennifer
    Franklin, Kathleen
    Reichelderfer, Renee
    Williams, Madison H.
    Williams, Ryan A.
    Smith, Sarah Allison
    Jones, Xavier
    Nooruddin, Zohra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Effects of Living in Food Priority Areas on Treatment and Outcomes in Patients With Stage III Nonsmall Cell Lung Cancer
    Hamza, M. A.
    Mohindra, P.
    Bentzen, S. M.
    Scilla, K.
    Burrows, W.
    Mehra, R.
    Rolfo, C.
    Miller, R. C.
    Vyfhuis, M. A. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E408 - E409
  • [23] Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer-A Narrative Review
    Facheris, Giorgio
    Cossali, Gianluca
    Imbrescia, Jessica
    La Mattina, Salvatore
    Mataj, Eneida
    Meli, Nicole
    Volpi, Giulia
    Triggiani, Luca
    Guerini, Andrea Emanuele
    Levi, Guido
    Grisanti, Salvatore
    di Monale e Bastia, Michela Buglione
    Borghetti, Paolo
    CANCERS, 2025, 17 (05)
  • [24] BUDGET IMPACT ANALYSIS OF INCORPORATING CRYOBALLON CRYOABLATION FOR TREATMENT OF ATRIAL FIBRILLATION IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Borghossian, S.
    Fujii, F. A.
    Moretti, P.
    VALUE IN HEALTH, 2020, 23 : S98 - S98
  • [25] Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer
    Shaverdian, Narek
    Offin, Michael D.
    Rimner, Andreas
    Shepherd, Annemarie F.
    Wu, Abraham J.
    Rudin, Charles M.
    Hellmann, Matthew D.
    Chaft, Jamie E.
    Gomez, Daniel R.
    RADIOTHERAPY AND ONCOLOGY, 2020, 144 : 101 - 104
  • [26] BUDGET IMPACT ANALYSIS OF CRIZOTINIB IN THE TREATMENT OF ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTH SYSTEM
    Alexandre, R. F.
    Squiassi, H. B.
    Santana, C. F.
    VALUE IN HEALTH, 2017, 20 (05) : A97 - A98
  • [27] Interdisciplinary multimodality management of stage III nonsmall cell lung cancer
    Huber, Rudolf M.
    De Ruysscher, Dirk
    Hoffmann, Hans
    Reu, Simone
    Tufman, Amanda
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (152):
  • [28] Optimal Treatment of Unresectable Stage III Non-Small Cell Lung Cancer
    Bradley, Jeffrey D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 853 - 855
  • [29] COMBINED-MODALITY TREATMENT FOR STAGE-III NONSMALL CELL LUNG-CANCER
    BONOMI, P
    LUNG CANCER, 1995, 12 : S41 - S52
  • [30] The treatment of Stage III nonsmall cell lung cancer using high dose conformal radiotherapy
    Sibley, GS
    Mundt, AJ
    Shapiro, C
    Jacobs, R
    Chen, G
    Weichselbaum, R
    Vijayakumar, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (05): : 1001 - 1007
12345